Consun Pharmaceutical Group Ltd. (C1P) Price & Analysis

Compare

2 Followers

C1P Stock Chart & Stats

Day’s Range― - ―

52-Week Range€0.07 - €1.17

Previous CloseN/A

Volume1.00K

Average Volume (3M)411.00

Market Cap

€912.78M

Enterprise Value€1.53B

Total Cash (Recent Filing)¥1.27B

Total Debt (Recent Filing)¥392.54M

Price to Earnings (P/E)6.5

Beta0.13

Next Earnings

Aug 21, 2025

EPS EstimateN/A

Next Dividend Ex-Date

Jun 10, 2025

Dividend Yield7.67%

Share Statistics

EPS (TTM)0.14

Shares Outstanding850,184,000

10 Day Avg. Volume1

30 Day Avg. Volume411

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)N/A

Price to Sales (P/S)1.52

Price to Cash Flow (P/CF)N/A

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€1.14

Price Target Upside23.91% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

---

Consun Pharmaceutical Group Ltd. News

PremiumCompany Announcements

Consun Pharmaceutical Group Ltd. Announces New Director Appointments

18d ago

PremiumCompany Announcements

Consun Pharmaceutical Announces Board Composition and Committee Structure

18d ago

PremiumCompany Announcements

Consun Pharmaceutical Appoints Renowned Nephrologist as Scientific Advisor

26d ago

PremiumDividends

Consun Pharmaceutical Group Ltd. (C1P) Declares Q2 Dividend: Important Details for Shareholders

26d ago

PremiumCompany Announcements

Consun Pharmaceutical Reports Strong 2024 Financial Results with Increased Revenue and Profit

1M ago

PremiumCompany Announcements

Consun Pharmaceutical Declares Final Dividend for 2024

1M ago

PremiumCompany Announcements

Consun Pharmaceutical Advances CKD Treatment with SK-08 Tablet Trial

1M ago

PremiumCompany Announcements

Consun Pharmaceutical Group Schedules Key Board Meeting for Financial Approvals

2M ago

See All DE:C1P News

---

Bulls Say, Bears Say

Bulls Say

Financial PerformanceDividend payout increased by 10ppts to 51% in 2024, with the higher payout expected to continue given solid financial position, translating into an attractive yield of 7%+.

Market PenetrationFurther penetration of uremic clearance granules in hospitals is expected to drive EPS growth, with significant penetration already achieved in top-tier hospitals.

Product DevelopmentPotential introduction of new drugs, with focus areas being identified, could be a catalyst and drive sales growth ahead.

Bears Say

Economic ConditionsSales volume growth slowdown due to a slowing economy.

Sales GrowthSlowdown in sales volume growth due to a slowing economy.

---

Financials

Quarterly

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

5.25%

Mutual Funds

― Other Institutional Investors

93.19% Public Companies and

Individual Investors

Detailed Ownership Overview >

C1P FAQ

What was Consun Pharmaceutical Group Ltd.’s price range in the past 12 months?

Consun Pharmaceutical Group Ltd. lowest stock price was €0.07 and its highest was €1.17 in the past 12 months.

What is Consun Pharmaceutical Group Ltd.’s market cap?

Consun Pharmaceutical Group Ltd.’s market cap is €912.78M.

When is Consun Pharmaceutical Group Ltd.’s upcoming earnings report date?

Consun Pharmaceutical Group Ltd.’s upcoming earnings report date is Aug 21, 2025 which is in 118 days.

How were Consun Pharmaceutical Group Ltd.’s earnings last quarter?

Consun Pharmaceutical Group Ltd. released its earnings results on Mar 26, 2025. The company reported €0.075 earnings per share for the quarter, beating the consensus estimate of N/A by €0.075.

Is Consun Pharmaceutical Group Ltd. overvalued?

According to Wall Street analysts Consun Pharmaceutical Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Consun Pharmaceutical Group Ltd. pay dividends?

Consun Pharmaceutical Group Ltd. pays a Annually dividend of €0.034 which represents an annual dividend yield of 7.67%. See more information on Consun Pharmaceutical Group Ltd. dividends here

What is Consun Pharmaceutical Group Ltd.’s EPS estimate?

Consun Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Consun Pharmaceutical Group Ltd. have?

Consun Pharmaceutical Group Ltd. has 850,184,000 shares outstanding.

What happened to Consun Pharmaceutical Group Ltd.’s price movement after its last earnings report?

Consun Pharmaceutical Group Ltd. reported an EPS of €0.075 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Consun Pharmaceutical Group Ltd.?

Currently, no hedge funds are holding shares in DE:C1P

---

Company Description

Consun Pharmaceutical Group Ltd.

Consun Pharmaceutical Group is a biotechnology company with sales operations throughout China. Its principal activities are making and selling pharmaceutical products. The company has two reportable segments: the Consun pharmaceutical segment, which is the key revenue driver, makes and sells modern Chinese medicines and medical contrast medium, and the Yulin pharmaceutical segment, which manufactures and sells traditional Chinese medicines. Consun derives revenue from kidney medicines, contrast medium, orthopedics medicines, dermatologic medicines, hepatobiliary medicines, medicines for women and children, and others.

---

C1P Stock 12 Month Forecast

Average Price Target

€1.14

▲(23.91% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.14</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2023","6":"Mar<br/>2024","9":"Aug<br/>2024","12":"Mar<br/>2025","25":"Mar<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,0.9,0.92,0.94,0.96,0.98,1,1.02,1.04,1.06,1.0799999999999998,1.0999999999999999,1.1199999999999999,{"y":1.14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,0.9,0.92,0.94,0.96,0.98,1,1.02,1.04,1.06,1.0799999999999998,1.0999999999999999,1.1199999999999999,{"y":1.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.88,0.9,0.92,0.94,0.96,0.98,1,1.02,1.04,1.06,1.0799999999999998,1.0999999999999999,1.1199999999999999,{"y":1.14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.5,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.52,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.47,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.45,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.48,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.52,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.61,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.61,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.03,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.88,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >

Technical Analysis

Similar Stocks

Sino Biopharmaceutical

―

LVZPF

Livzon Pharmaceutical Group

―

SFOSF

Shanghai Fosun Pharmaceutical (Group) Co

―

640

China Resources Pharmaceutical Group Ltd.

―

Compare DE:C1P Stocks >

Best Analysts Covering C1P

1 Year

Mark Kong CFADBS

1 Year Success Rate

2/3 ratings generated profit

1 Year Average Return

-3.67%

reiterated a buy rating 30 days ago

Copying Mark Kong CFA's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of -3.67% per trade.

Best Analyst Covering >

Popular Stocks

---

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing